417 related articles for article (PubMed ID: 33678314)
1. The Management of Gout in Renal Disease.
Estiverne C; Mount DB
Semin Nephrol; 2020 Nov; 40(6):600-613. PubMed ID: 33678314
[TBL] [Abstract][Full Text] [Related]
2. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
7. Management of Gout and Hyperuricemia in CKD.
Vargas-Santos AB; Neogi T
Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
[TBL] [Abstract][Full Text] [Related]
8. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
9. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Wang S
Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
[TBL] [Abstract][Full Text] [Related]
11. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
12. Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Chung TT; Yu KH; Kuo CF; Luo SF; Chiou MJ; Lan WC; Chen JS; Tseng WY; Hsieh AH; Wang LC
Arthritis Res Ther; 2019 Sep; 21(1):210. PubMed ID: 31533805
[TBL] [Abstract][Full Text] [Related]
13. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Curiel RV; Guzman NJ
Semin Arthritis Rheum; 2012 Oct; 42(2):166-78. PubMed ID: 22560299
[TBL] [Abstract][Full Text] [Related]
14. Major unanswered questions in the clinical gout field.
Stamp LK
Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
[TBL] [Abstract][Full Text] [Related]
15. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Kim SH; Lee SY; Kim JM; Son CN
Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
[TBL] [Abstract][Full Text] [Related]
16. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
17. Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Deng JH; Zhong GW; Zhang JX
Ann Palliat Med; 2022 Aug; 11(8):2789-2791. PubMed ID: 35948476
[No Abstract] [Full Text] [Related]
18. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat for the treatment of hyperuricaemia in gout.
Robinson PC; Dalbeth N
Expert Opin Pharmacother; 2018 Aug; 19(11):1289-1299. PubMed ID: 30024787
[TBL] [Abstract][Full Text] [Related]
20. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]